Info@ThinkPinkRocks.com

AcelRx provides update on Zalviso (sufentanil sublingual tablet system)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a regulatory update on Zalviso (sufentanil sublingual tablet system) intended for the management of moderate-to-severe acute pain in adult patients in the hospital setting.

Read More:
AcelRx provides update on Zalviso (sufentanil sublingual tablet system)

Share
1 Comment
  1. whoah this blog is excellent i like studying your posts. Stay up the good paintings! You know, lots of individuals are hunting round for this info, you can aid them greatly.
    bague bulgari occasion pas cher http://www.aluxury.nl/fr/

Leave a Reply

Solve : *
12 + 3 =